Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 3
1987 1
1988 5
1989 3
1990 13
1991 5
1992 4
1993 1
1994 3
1995 3
1996 4
1998 2
1999 4
2000 1
2002 1
2003 3
2005 1
2007 1
2009 2
2011 2
2013 3
2014 3
2017 1
2018 2
2019 2
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

76 results
Results by year
Filters applied: . Clear all
Page 1
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Katayama R, Gong B, Togashi N, Miyamoto M, Kiga M, Iwasaki S, Kamai Y, Tominaga Y, Takeda Y, Kagoshima Y, Shimizu Y, Seto Y, Oh-Hara T, Koike S, Nakao N, Hanzawa H, Watanabe K, Yoda S, Yanagitani N, Hata AN, Shaw AT, Nishio M, Fujita N, Isoyama T. Katayama R, et al. Among authors: oh hara t. Nat Commun. 2019 Aug 9;10(1):3604. doi: 10.1038/s41467-019-11496-z. Nat Commun. 2019. PMID: 31399568 Free PMC article.
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Okada K, Araki M, Sakashita T, Ma B, Kanada R, Yanagitani N, Horiike A, Koike S, Oh-Hara T, Watanabe K, Tamai K, Maemondo M, Nishio M, Ishikawa T, Okuno Y, Fujita N, Katayama R. Okada K, et al. Among authors: oh hara t. EBioMedicine. 2019 Mar;41:105-119. doi: 10.1016/j.ebiom.2019.01.019. Epub 2019 Jan 17. EBioMedicine. 2019. PMID: 30662002 Free PMC article.
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.
Takahashi K, Seto Y, Okada K, Uematsu S, Uchibori K, Tsukahara M, Oh-Hara T, Fujita N, Yanagitani N, Nishio M, Okubo K, Katayama R. Takahashi K, et al. Among authors: oh hara t. Thorac Cancer. 2020 Mar;11(3):581-587. doi: 10.1111/1759-7714.13299. Epub 2020 Jan 13. Thorac Cancer. 2020. PMID: 31943796 Free PMC article.
High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
Ariyasu R, Nishikawa S, Uchibori K, Oh-Hara T, Yoshizawa T, Dotsu Y, Koyama J, Saiki M, Sonoda T, Kitazono S, Yanagitani N, Horiike A, Inase N, Kasahara K, Nishio M, Katayama R. Ariyasu R, et al. Among authors: oh hara t. Lung Cancer. 2018 Mar;117:1-6. doi: 10.1016/j.lungcan.2017.12.018. Epub 2018 Jan 4. Lung Cancer. 2018. PMID: 29496249
76 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page